Phase I study using weekly Taxol (T) and gemcitabine (G) in patients with advanced non small cell lung cancer (NSCLC)

被引：0
|
作者：
De Pas, T
De Braud, F
Sessa, C
Nole, F
Minchella, I
Catania, C
Goldhirsch, A
机构：
[1] EIO, Milano, Italy
[2] HS Giovanni, Bellinzona, Switzerland
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
375
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [21] Gemcitabine and cisplatin in advanced non small cell lung cancer (NSCLC)
    Garcia-Gomez, R
    Lopez-Criado, P
    Guevara, S
    Lahoz, C
    Chaib, C
    Gonzalez, C
    Santiago, J
    De Alvaro, J
    Carrion, R
    Perez-Manga, G
    ANNALS OF ONCOLOGY, 1998, 9 : 93 - 94
  • [22] Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer
    David Aguiar
    José Aguiar
    Uriel Bohn
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 152 - 158
  • [23] Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer
    Aguiar, D
    Aguiar, J
    Bohn, U
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (02) : 152 - 158
  • [24] Taxol-carboplatin in advanced non small cell lung cancer (NSCLC).
    González, A
    Favida, JL
    Amenedo, M
    García, J
    Losada, G
    Saigado, M
    Montanos, MJ
    Rodriguez, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S69 - S69
  • [25] WEEKLY DOCETAXEL (TXT) WITH WEEKLY GEMCITABINE AS PROLONGED INFUSION (GEM) IN PATIENTS WITH ADVANCED, PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC): PRELIMINARY REPORT OF A PHASE II STUDY
    Antonelli, Giovanna
    Priolo, Domenico
    Amadio, Placido
    Colina, Paolo
    Vitale, Felice
    Ferrau, Francesco
    ANNALS OF ONCOLOGY, 2004, 15 : 31 - 31
  • [26] Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Rademaker-Lakhai, JM
    Crul, M
    Pluim, D
    Sparidans, RW
    Baas, P
    Beijnen, JH
    van Zandwijk, N
    Schellens, JHM
    ANTI-CANCER DRUGS, 2005, 16 (09) : 1029 - 1036
  • [27] Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer
    Blackstock, AW
    Lesser, GJ
    Fletcher-Steede, J
    Case, LD
    Tucker, RW
    Russo, SM
    White, DR
    Miller, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (05): : 1281 - 1289
  • [28] Phase I study of weekly cisplatin (P) and weekly or four weekly taxol (T) in patients with advanced ovarian cancer
    vanderBurg, M
    deWit, R
    Logmans, A
    vanLent, M
    Stoter, G
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1108 - 1108
  • [29] Phase II study of Gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC)
    De las Penas, R
    Busquier, I
    Munarriz, J
    Lopez, A
    Llorente, R
    Alberola, V
    Frau, A
    ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [30] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
12345